We studied the antibacterial activity and clinical efficacy of cefluprenam (CFLP), a new injectable cephalosporin antibiotic, in urinary tract infections. 1) Antibacterial activity: The MICs of CFLP were measured against 210 clinical isolates of 14 species from urinary tract infections and compared with those of ceftazidime (CAZ), cefoperazone (CPZ), latamoxef (LMOX) and imipenem (IPM). In general, the antibacterial activity of CFLP was superior to those of other compared cephems except for IPM, but slightly inferior to that of IPM. 2) Clinical efficacy: Fourteen patients with complicated urinary tract infection were treated once or twice a day with 0.5g or 1.0g of CFLP. Out of 14, 12 cases were evaluated according to the criteria of the apanese UTI Committee. The overall clinical efficacy rate was 66.7%(8/12). Bacteriologically, 17 of 20 strains (85%) were eradicated. 3) Side effect: No clinical side effects and no abnormal laboratory changes were observed in any cases.
|Number of pages||7|
|Journal||Japanese Journal of Chemotherapy|
|Publication status||Published - Jan 1 1995|
ASJC Scopus subject areas
- Pharmacology (medical)